Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Public ClinicalTrials.gov record NCT07227012. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 AS MONOTHERAPY AND COMBINATION THERAPY IN ADULT PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have locally advanced or metastatic HCC. * Is not a candidate for complete surgical or loco-regional therapies. * Have not received any whole-body treatment for HCC. Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.
Study identification
- NCT ID
- NCT07227012
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 138 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2025
- Primary completion
- Oct 17, 2027
- Completion
- Oct 16, 2028
- Last update posted
- Aug 16, 2026
2025 – 2028
United States locations
- U.S. sites
- 41
- U.S. states
- 8
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine | California | 92612 | Recruiting |
| UCI Health - Irvine Infusion Pharmacy ACC | Irvine | California | 92612 | Recruiting |
| UCI Health - Irvine | Irvine | California | 92612 | Recruiting |
| Keck Hospital of USC | Los Angeles | California | 90033 | Recruiting |
| Los Angeles General Medical Center | Los Angeles | California | 90033 | Recruiting |
| USC/Norris Comprehensive Cancer Center / Investigational Drug Services | Los Angeles | California | 90033 | Recruiting |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Recruiting |
| UC Irvine Health - Chao Family Comprehensive Cancer Center | Orange | California | 92868 | Recruiting |
| Keck Medical Center of USC Pasadena | Pasadena | California | 91105 | Recruiting |
| Moffitt Cancer Center at Speros | Land O' Lakes | Florida | 34638 | Recruiting |
| Moffitt Cancer Center at SouthShore | Ruskin | Florida | 33570 | Recruiting |
| Moffitt Cancer Center - International Plaza | Tampa | Florida | 33607 | Recruiting |
| Moffitt Cancer Center - McKinley Campus | Tampa | Florida | 33612 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| Moffitt McKinley Hospital | Tampa | Florida | 33612 | Recruiting |
| Moffitt Cancer Center at Wesley Chapel | Wesley Chapel | Florida | 33544 | Recruiting |
| Memorial Hospital | Shiloh | Illinois | 62269 | Recruiting |
| Siteman Cancer Center - Shiloh | Shiloh | Illinois | 62269 | Recruiting |
| Allina Health Cancer Institute - Mercy Hospital | Coon Rapids | Minnesota | 55433 | Recruiting |
| Allina Health Cancer Institute - Abbott Northwestern Hospital | Minneapolis | Minnesota | 55407 | Recruiting |
| Allina Health Cancer Institute - United Hospital | Saint Paul | Minnesota | 55102 | Recruiting |
| Siteman Cancer Center - St. Peters | City of Saint Peters | Missouri | 63376 | Recruiting |
| Siteman Cancer Center - West County | Creve Coeur | Missouri | 63141 | Recruiting |
| Siteman Cancer Center - North County | Florissant | Missouri | 63031 | Recruiting |
| Saint Luke's Cancer Institute | Kansas City | Missouri | 64111 | Recruiting |
| Saint Luke's Hospital of Kansas City | Kansas City | Missouri | 64111 | Recruiting |
| Siteman Cancer Center | St Louis | Missouri | 63108 | Recruiting |
| Barnes-Jewish Hospital | St Louis | Missouri | 63110 | Recruiting |
| Washington University School of Medicine - Siteman Cancer Center | St Louis | Missouri | 63110 | Recruiting |
| Siteman Cancer Center - South County | St Louis | Missouri | 63129 | Recruiting |
| Renown Health Medical Oncology | Reno | Nevada | 89502 | Recruiting |
| Renown Office of Clinical Research | Reno | Nevada | 89502 | Recruiting |
| Renown Regional Medical Center | Reno | Nevada | 89502 | Recruiting |
| Duke Cancer Center Cary | Cary | North Carolina | 27518 | Recruiting |
| Duke Cancer Center - Investigational Chemotherapy Service | Durham | North Carolina | 27710 | Recruiting |
| Duke Cancer Center | Durham | North Carolina | 27710 | Recruiting |
| Duke University - Main Hospital and Clinics | Durham | North Carolina | 27710 | Recruiting |
| Duke Cancer Center Raleigh | Raleigh | North Carolina | 27609 | Recruiting |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | Not yet recruiting |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | Recruiting |
| University of Washington Medical Center- Montlake | Seattle | Washington | 98195 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07227012, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07227012 live on ClinicalTrials.gov.